Join

Compare · NUVL vs PFE

NUVL vs PFE

Side-by-side comparison of Nuvalent Inc. (NUVL) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NUVL and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PFE is the larger of the two at $304.95B, about 486.6x NUVL ($626.7M).
  • Over the past year, NUVL is up 39.0% and PFE is up 17.1% - NUVL leads by 21.8 points.
  • PFE has been more active in the news (10 items in the past 4 weeks vs 6 for NUVL).
  • PFE has more recent analyst coverage (25 ratings vs 24 for NUVL).
PerformanceNUVL+38.97%PFE+17.13%
2025-04-28+0.00%2026-04-24
MetricNUVLPFE
Company
Nuvalent Inc.
Pfizer Inc.
Price
$104.53-3.26%
$26.98+1.20%
Market cap
$626.7M
$304.95B
1M return
+6.66%
-1.21%
1Y return
+38.97%
+17.13%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
6
10
Recent ratings
24
25
NUVL

Nuvalent Inc.

Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

PFE

Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Latest NUVL

Latest PFE